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Abstract
Objectives: Methamphetamine (MA) dependence contributes to neurotoxicity and neurocognitive deficits. Although
combined alcohol and MA misuse is common, how alcohol consumption relates to neurocognitive performance among
MA users remains unclear. We hypothesized that alcohol and MA use would synergistically diminish neurocognitive
functioning, such that greater reported alcohol consumption would exert larger negative effects on neurocognition among
MA-dependent individuals compared to MA-nonusing persons. Methods: Eighty-seven MA-dependent (MAþ) and
114 MA-nonusing (MA−) adults underwent neuropsychological and substance use assessments. Linear and logistic
regressions examined the interaction between MA status and lifetime average drinks per drinking day on demographically
corrected global neurocognitive T scores and impairment rates, controlling for recent alcohol use, lifetime cannabis use,
WRAT reading performance, and lifetime depression. Results: MAþ displayed moderately higher rates of impairment and
lower T scores compared to MA−. Lifetime alcohol use significantly interacted with MA status to predict global
impairment (ORR= 0.70, p= .003) such that greater lifetime alcohol use increased likelihood of impairment in MA−,
but decreased likelihood of impairment in MAþ. Greater lifetime alcohol use predicted poorer global T scores among
MA− (b=−0.44, p= .030) but not MAþ (b= 0.08, p= .586). Conclusions: Contrary to expectations, greater lifetime
alcohol use related to reduced risk of neurocognitive impairment among MA users. Findings are supported by prior
research identifying neurobiological mechanisms by which alcohol may attenuate stimulant-driven vasoconstriction and
brain thermotoxicity. Replication and examination of neurophysiologic mechanisms underlying alcohol use in the context
of MA dependence are warranted to elucidate whether alcohol confers a degree of neuroprotection.
Keywords: Substance-related disorders, methamphetamine, ethanol, neuropsychology, neuroprotection, cognitive
dysfunction
INTRODUCTION
Methamphetamine (MA) is a highly addictive and widely
used psychostimulant that induces adverse effects on the cen-
tral nervous system (CNS), predominantly through alteration
of monoaminergic pathways. Chronic exposure to MA and
other amphetamines is associated with a host of neurotoxic
processes including gliosis, neuronal apoptosis, oxidative
stress, brain thermotoxicity, and neuroinflammation (Cadet
et al., 2003; Yu et al., 2015). Consequently, conditions of
neurochemical and cerebrovascular abnormalities, including
increased blood–brain barrier permeability and ischemic
stroke, are more prevalent among stimulant users (Sajja
et al., 2016; Turowski & Kenny, 2015; Yen et al., 1994)
and can disrupt neural circuits, particularly fronto-striatal
systems that support neurocognitive abilities. It has beenwidely
documented thatMA-dependent individuals are vulnerable to a
constellation of neurocognitive deficits including impairments
in episodic memory, executive functioning, working memory,
information processing speed, verbal fluency, attention, and
motor skills (Kalechstein et al., 2003; Scott et al., 2007;
Wood et al., 2014).
Whereas it is evident that MA dependence is associated
with neurocognitive dysfunction, the severity of such neuro-
cognitive deficits remains unclear. Synthesis of clinical stud-
ies comparing neurocognitive profiles of MA-dependent
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individuals to non-using controls not only indicates amild-to-
moderate deleterious effect of MA on neurocognition, but
also reveals considerable inter-individual variability in which
manyMA-dependent persons perform within normative stan-
dards whereas others may exhibit severe deficits (Dean et al.,
2013; Hart et al., 2012). Variation in use patterns ofMA alone
does not appear to account for these individual differences in
vulnerability to MA-related brain dysfunction as the existing
human literature has generally failed to find a consistent dose-
dependent relationship between MA exposure parameters
and neurocognitive impairment (Chang et al., 2002;
Cherner et al., 2010; Johanson et al., 2006; McCann et al.,
2008). Given the unimpressive predictive utility of MA expo-
sure parameters as moderators of neurocognitive impairment,
susceptibility to MA-related neurocognitive dysfunction may
be better explained by the influence of other modulating
variables.
Considering that MA is seldom used on its own, patterns
of polysubstance use among primary MA users may modu-
late vulnerability to neurocognitive impairment. Alcohol is
of particular interest as it is the most commonly used secon-
dary substance among primary MA users (Halkitis et al.,
2005; Wang et al., 2017) and heavy drinkers are 4–5 times
more likely to report using MA as compared to non-drinkers
(Bujarski et al., 2014; Caetano & Weisner, 1995; Furr et al.,
2000). The detrimental effects of chronic excessive alcohol
consumption on CNS and neurocognitive functioning have
been extensively studied. Briefly, heavy alcohol-related risks
for brain damage include disruption to neurotransmitter sys-
tems, neuroinflammation, neurodegeneration, and cerebro-
vascular disease (Gorelick, 1987; Oscar-Berman &
Marinkovic, 2003; Syapin et al., 2005). Long-term alcohol
misuse has been linked to alterations in frontal and limbic
neural circuitry, most commonly resulting in neuropsycho-
logical deficits of episodic memory, problem solving, and
cognitive control (Bernardin et al., 2014; Oscar-Berman
et al., 2014; Sullivan et al., 2010).
Given thatMA and alcohol independently disrupt overlap-
ping neurobiological mechanisms, neuroanatomical struc-
tures, and neurobehavioral functions, one may expect a
synergistic neurotoxic effect of combined MA and alcohol
misuse. Previous animal studies have reported that alcohol
enhances the absorption and delivery of MA in the brain
(Liang et al., 2012). Additional animal model research has
shown that concurrent exposures to MA and alcohol synerg-
istically increase oxidative stress in the rat hippocampus and
contribute to behavioral impairments in learning, discrimina-
tion, and spatial working memory above and beyond the
effects of either substance alone (Vahed, 2014; Yamamura
et al., 1992). In vitro human brain tissue models provide con-
verging evidence that both alcohol and MA impair glucose
metabolism in astrocytes and neurons, a process that is a pre-
cursor to oxidative stress-mediated neurotoxicity (Abdul
Muneer et al., 2011a, 2011b). Although less is known about
combined MA and alcohol-induced biological damage in
vivo, there is evidence that acute as well as repeated concur-
rent exposure induces adverse vascular effects, including
increased heart rate and myocardial oxygen consumption
(Kirkpatrick et al., 2012; Mendelson et al., 1995).
Consistent with neurocognitive profiles of adult MA users,
pediatric studies demonstrate that prenatal exposures to
MA and alcohol synergistically damage fronto-striatal net-
works and compromises working memory abilities in chil-
dren aged 5–15 (Roussotte et al., 2011; Sowell et al., 2010).
Chronic exposure to cocaine, another potent psychostimu-
lant, is associated with moderate deficits in neurocognition
across a range of domains, with the largest effects in executive
function, working memory, and verbal learning/memory
(Potvin et al., 2014). Whereas combined cocaine and alcohol
use has been linked to altered neurophysiological activity
(Althobaiti & Sari, 2016), including abnormal cerebral blood
perfusion (Gottschalk &Kosten, 2002), elevated heart rate and
cortisol levels (Farré et al., 1997), and dysregulated dopami-
nergic and serotonergic transmission (Horowitz & Torres,
1999), literature on the neurocognitive effects of comorbid
cocaine and alcohol use disorders is mixed. Some studies
report that increasing alcohol use provides an additive
deleterious effect on neurocognition in primary cocaine users
(Bolla et al., 2000; Woicik et al., 2009) and can also attenuate
improvements in verbal memory following abstinence from
cocaine (Rosselli & Simmers, 2016). Nevertheless, others have
failed to detect a significant impact of alcohol consumption on
neurocognition in the context of cocaine dependence (Abi-
Saab et al., 2005; Bolla et al., 1999; Goldstein et al., 2004).
Although combined alcohol and MA misuse is common
and may result in a convergence of mechanisms of neural
injury, it remains unclear how historical patterns of alcohol
use relate to neurocognitive functioning among primary
MA users. Therefore, the current study aimed to address this
gap in knowledge by examining the relationships between a
continuous estimate of lifetime alcohol consumption and neu-
rocognitive functioning in a sample of MA-dependent and
MA-nonusing individuals. We hypothesized that greater
reported lifetime alcohol consumption would contribute to
poorer neurocognitive functioning regardless of MA depend-
ence, but would exhibit significantly larger effects among
MA-dependent individuals compared to MA-nonusing per-
sons. Examination of these associations may assist in identi-
fying specific risk factors for neurocognitive impairment
among MA-dependent individuals, and may guide develop-
ment of targeted polysubstance use prevention and treatment
strategies for this population.
METHODS
Participants
Eighty-seven MA-dependent (MAþ) and 114 MA-nonusing
comparison (MA−) participants were evaluated at the HIV
Neurobehavioral Research Program (HNRP) at the
University of California, San Diego (UCSD), as part of fed-
erally funded, institutionally approved projects focusing on
neuroAIDS effects of methamphetamine. All were recruited
from substance dependence recovery programs or from the
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general San Diego community, and gave written informed
consent as approved by the UCSD Institutional Review
Board. Participants were confirmed to beHIV andHCV unin-
fected by standard antibody testing and were free of medical
conditions that might confound interpretation of neurocogni-
tive testing results, such as traumatic brain injury, stroke, or
epilepsy. The MAþ individuals met criteria for a lifetime
diagnosis of MA dependence according to the Structured
Clinical Interview for DSM-IV (SCID-IV; Spitzer et al.,
1995), with use within the previous 18 months. The MA−
group consisted of participants who never met criteria for
amphetamine use disorders and were not habitual users of
any stimulant. Exclusion criteria for both groups included
other substance dependence, except alcohol or cannabis,
within 5 years, or abuse within the past 12 months.
Participants were requested to be abstinent from MA for at
least 10 days prior to testing and were required to show a
negative urine toxicology for any non-prescribed substance
except cannabis, as well as a negative Breathalyzer test for
alcohol on the day of neurocognitive testing.
Procedures
Substance use and psychiatric information
The methods of drug use characterization have been described
elsewhere (Cherner et al., 2010; Gonzalez et al., 2004). Briefly,
participants were administered structured interviews from
selectedmodules of the SCID-IV to assess history of substance
dependence and mood disorder. A semi-structured timeline
follow-back interview was administered to gather a detailed
history of quantity, frequency, and duration of substance con-
sumption over a participant’s lifetime. Variables of alcohol,
MA, and cannabis use derived from this interview were age
of first use, days since last use, estimated lifetime grams
(MA and cannabis) and drinks (alcohol) consumed, estimated
lifetime days of use, and average grams per day of use (MAand
cannabis) and average drinks per drinking day (referred to as
“lifetime average daily alcohol use”). We conceptualized life-
time average daily alcohol use, an establishedmetric utilized to
quantify alcohol misuse (Dawson et al., 2005), as a proxy for
typical level of alcohol use throughout the lifetime. Parameters
of cannabis use were specifically examined because study
criteria did not exclude recent cannabis use and prior research
has suggested cannabis may be associated with better neuro-
cognitive functioning among MA users (Gonzalez et al.,
2004). Table 1 displays the MA use parameters of the
MAþ group in addition to the 14 MA− participants who
reported having tried MA occasionally (fewer than 10 lifetime
uses). Current mood symptoms were assessed using the Beck
Depression Inventory II (BDI-II; Beck et al., 1996).
Neurocognitive assessment
All participants completed a comprehensive neurocognitive
evaluation that has been described in detail elsewhere
(Rippeth et al., 2004). In short, this neurocognitive test
battery covers seven ability domains: verbal fluency,
abstraction/executive functioning, processing speed, learn-
ing, delayed recall, attention/working memory, and complex
motor skills (see Supplementary Table 1 for individual tests
in each domain). Raw test scores were converted to demo-
graphically corrected standard T scores (mean of 50 and stan-
dard deviation of 10) that adjusted for the effects of age,
education, sex, and race/ethnicity, as appropriate (Heaton
et al., 2004; Heaton et al., 2003; Norman et al., 2011). The
demographically corrected T scores for each measure were
averaged to compute global and domain-specific T scores
within each neurocognitive ability area. To determine the
presence of neurocognitive impairment, individual test
T scores were converted to deficit scores that give differential
weight to impaired scores (>1 standard deviation below the
mean), as opposed to normal scores. Deficit scores range
from 0 to 5 according to the following T scores and impair-
ment descriptors, based on half standard deviation decre-
ments: 0= T ≥40 (no impairment); 1= T 35–39 (mild);
2= T 30–34 (mild-to-moderate); 3= T 25–29 (moderate);
4= T 20–24 (moderate-to-severe); 5= T <20 (severe).
Deficit scores for each measure were averaged across the
entire test battery to derive a global deficit score (GDS)
and within each domain to derive domain-specific deficit
scores (DDS). Consistent with prior studies (Blackstone
et al., 2012; Carey et al., 2004), the presence of global impair-
ment was defined by GDS ≥ 0.5 and domain-specific impair-
ment by DDS > 0.5. The dichotomous GDS classification of
impaired/unimpaired was used as an outcome measure in
logistic regression analyses predicting global neurocognitive
impairment.
Table 1. Methamphetamine use parameters by methamphetamine status
Methamphetamine use parameter MA− MAþ
Mean (SD) or median [IQR] (n= 14/114 only) (n= 87)
Lifetime days of use 30 [7–30] 2640 [780–4706]
Lifetime grams consumed 1.9 [1.5–1.9] 1497.7 [342.4–4730.7]
Lifetime average daily use (grams/day) 0.1 [0.1–0.1] 0.7 [0.3–1.5]
Days since last use 2739 [1735–5022] 75 [30–152]
Age of first use 25.3 (10.34) 23 (10.57)
Note. MA – use represents occasional experimentation.
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Statistical Analysis
MA group comparisons of neuropsychological outcomes (i.e.,
T scores and impairment status), demographics, depressive
symptoms, alcohol and cannabis use, and other lifetime sub-
stance dependence were conducted using Student’s t tests,
Wilcoxon Rank Sum tests, chi-square tests, and Fisher’s exact
tests as appropriate. MA group differences in neurocognitive
performance were evident across domains. Given this non-
specific pattern of MA group differences, and in order to limit
multiple comparisons, we present the global T scores and
global impairment classifications as outcome variables in
linear and logistic regression analyses, respectively. Details
of domain-specific results appear in Supplementary Table 2.
We first tested whether MA group differences in global
functioning were attenuated by differences in estimated
premorbid ability and neuropsychiatric factors by entering
MA status along with performance on the Wide Range
Achievement Test (version 3 or 4) Reading subtest (WRAT;
Wilkinson & Robertson, 2006), lifetime major depressive dis-
order (MDD), and lifetime average daily cannabis as covariates
into each model. Age, education, race/ethnicity, and sex were
not considered as model covariates because they were already
included in the neurocognitive test T score demographic
adjustments. Next, we added lifetime average daily alcohol
use and days since last alcohol use to test whether historical
alcohol use, controlling for recency of alcohol use, incremen-
tally predicted global functioning independent of MA status.
Finally, an interaction term between MA status and lifetime
average daily alcohol use was added to examine whether
lifetime alcohol usemodulatedMAgroup differences in neuro-
cognition. To probe interaction effects, simple slope analyses
were conducted by examining the association of global func-
tioningwith lifetime average daily alcohol usewithin eachMA
group, adjusting for covariates. To avoidmulticollinearitywith
lifetimeMDD, BDI-II was not included as a covariate in initial
models. Instead, BDI-II was added as a post-hoc covariate to
Table 2. Demographic and clinical characteristics
Variable MA− MAþ
p-valueMean (SD), Median [IQR], or N (%) (n= 114) (n= 87)
Demographics
Age (years) 37.2 (12.21) 38.6 (10.79) .40
Education (years) 14.1 (2.08) 12.6 (2.20) <.0001
WRAT reading 105.4 (10.14) 99.1 (9.27) <.0001
Sex (male) 99 (86.8%) 81 (93.1%) .14
Ethnicity (non-Hispanic White) 73 (64.0%) 59 (67.8%) .58
Depressive symptoms
Lifetime MDD 24 (21.1%) 34 (39.1%) <.01
Current MDD 3 (2.6%) 8 (9.2%) .06
BDI-II 2 (0–6) 11 (4–20) <.001
Alcohol use
Lifetime alcohol dependence 10 (8.8%) 32 (36.8%) <.001
Lifetime drinking days 663 [127–1750] 1453 [470–3544] <.001
Lifetime drinks consumed 2077 [271–5902] 8184 [2122–22,554] <.001
Lifetime average daily use (drinks/day) 3.7 (2.53) 6.1 (4.00) <.001
Days since last use 6.5 [2–99] 116 [14–411] <.001
Age of first use 17.8 (4.29) 15.0 (4.63) <.001
Cannabis use
Lifetime cannabis dependence 4 (3.5%) 20 (23.0%) <.001
Current cannabis dependence 1 (0.9%) 1 (1.2%) 1.000
Lifetime days of use 31 [0–395] 1261 [156–4176] <.001
Lifetime grams consumed 5 [0–65.3] 496 [37.5–2465] <.001
Lifetime average daily use (grams/day) 0.07 [0–0.25] 0.50 [0.19–2.07] <.001
Days since last use 274 [12.5–2739] 365 [76–2739] .48
Age of first use 16.0 (3.75) 14.1 (3.76) <.001
Other lifetime substance dependence
Cocaine 0 (0%) 14 (16.1%) <.001
Hallucinogen 0 (0%) 2 (2.3%) .19
Opioid 0 (0%) 6 (6.9%) <.01
Inhalant 0 (0%) 1 (1.2%) .46
Sedative 0 (0%) 0 (0%) –
PCP 0 (0%) 0 (0%) –
Note. Alcohol dependence greater than 12 months ago; other drug dependence greater than 5 years ago; cannabis may be recent.
MA=methamphetamine status; WRAT Reading=Wide Range Achievement Test; MDD=major depressive disorder; BDI-
II=Beck Depression Inventory-II.
4 R. Saloner et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1355617719000493
Downloaded from https://www.cambridge.org/core. Access paid by the UC San Diego Library, on 24 Jun 2019 at 17:31:06, subject to the Cambridge Core terms of use, available at
final models in order to rule out the potential confounding in-
fluence of active depressive symptoms. To enhance interpret-
ability of the logistic regression results predicting likelihood
of global neurocognitive impairment, we present odds ratios
(OR) estimatedwith 95%confidence intervals (CI).All analyses
were performed using JMP Pro version 12.0.1 (JMP®,
Version <12.0.1>. SAS Institute Inc., Cary, NC, 1989–2007).
RESULTS
Demographic and Clinical Characteristics
Demographic and clinical characteristics for each MA group
are displayed in Table 2. Although groups were comparable
with respect to age, sex, and race/ethnicity, the MAþ group
had significantly fewer years of education and lower WRAT
performance. The MAþ group displayed higher BDI-II
scores as well as greater prevalence of lifetime non-MA sub-
stance use disorders and lifetime MDD.
With respect to parameters of alcohol consumption, the
MAþ group generally reported a more extensive history of
drinking behavior than the MA– group. Specifically, MAþ
individuals on average drank on more days, consumed more
total drinks, and subsequently had a greater lifetime average
daily alcohol use than MA− individuals (p < .001).
Furthermore, the MAþ group had a younger age of first alco-
hol use (p < .001). Conversely, the MA– group reported sig-
nificantly fewer days since last alcohol use than the MAþ
group (p < .0001). With the exception of days since last can-
nabis use (p= .48), MAþ individuals also reported a more
extensive history of cannabis use. Spearman’s correlations
were conducted to examine the associations between lifetime
average daily alcohol, cannabis, andMA use. Alcohol use pos-
itively correlated with both MA use (rs= .21, p= .038) and
cannabis use (rs= .36, p< .001) indicating that MAþ individ-
uals with elevated lifetime drinking patterns were also more
likely to show elevated lifetimeMA and cannabis use patterns.
Although lifetime average daily MA use positively correlated
with lifetime average daily cannabis use, this association failed
to reach statistical significance (rs= .13, p= .194)
Neurocognitive Performance Across MA Status
With respect to global performance, the MAþ group had
significantly lower global T scores (47.5 vs. 49.9; d=−0.45;
p= .002) and higher impairment rates (27.6% vs. 15.8%;
OR= 2.03; p= .042) compared to the MA– group. Domain-
specific neurocognitive T scores and impairment rates for
MA groups are displayed in Supplementary Table 2. The
MAþ group demonstrated worse neurocognitive performance
compared to the MA– group across all ability areas for both
T scores (Cohen’s d range: −0.07–0.48) and impairment rates
(OR range: 1.18–2.13).
Interaction of Lifetime Average Daily Alcohol Use
and MA Status Predicts Neurocognitive Performance
Table 3 reports results for the stepwise multivariable linear
regression analysis predicting global T scores. Step 1, which
Table 3. Stepwise multivariable linear and logistic regression models predicting global T scores and impairment
Outcome Step 1 Step 2 Step 3
Global T scores b 95% CI p b 95% CI p b 95% CI p
WRAT 0.09 [0.01, 0.17] .020 0.09 [0.01, 0.17] .026 0.07 [−0.00, 0.15] .061
LT MDDa 0.64 [−1.04, 2.31] .453 0.68 [−1.04, 2.40] .434 0.89 [−0.83, 2.61] .307
Lifetime cannabis useb −0.29 [−1.20, 0.61] .521 −0.24 [−1.16, 0.68] .605 −0.38 [−1.30, 0.54] .421
MAc −1.75 [−3.37, −0.13] .034 −1.67 [−3.36, 0.03] .054 −1.60 [−3.29, 0.09] .063
Days since last alcohol use −0.00 [−0.00, 0.00] .983 −0.00 [−0.00, 0.00] .938
Lifetime alcohol useb,d −-0.08 [−0.31, 0.15] .502 −0.41 [−0.80, −0.01] .043
MAc × Lifetime alcohol useb 0.50 [0.01, 0.98] .044
Outcome Step 1 Step 2 Step 3
Global impairment OR 95% CI p OR 95% CI p OR 95% CI p
WRAT 0.96 [0.92, 1.00] .078 0.96 [0.92, 1.00] .069 0.97 [0.93, 1.01] .143
LT MDDa 0.82 [0.35, 1.80] .635 0.77 [0.32, 1.72] .530 0.64 [0.26, 1.48] .308
Lifetime cannabis useb 0.71 [0.39, 1.13] .206 0.73 [0.39, 1.15] .232 0.76 [0.41, 1.22] .310
MAc 2.05 [0.96, 4.39] .064 2.34 [1.07, 5.26] .035 2.23 [1.03, 4.85] .043
Days since last alcohol use 1.00 [1.00, 1.00] .610 1.00 [1.00, 1.00] .530
Lifetime alcohol usebd 0.95 [0.84, 1.05] .345 1.19 [0.99, 1.42] .057
MAc × Lifetime alcohol useb 0.70 [0.54, 0.88] .003
OR= odds ratio; CI= confidence interval; WRAT=Wide Range Achievement Test; MA=methamphetamine status; MDD=major depressive disorder.
a Lifetime diagnosis of MDD compared to no lifetime diagnosis of MDD.
b Represents lifetime average daily use.
c Effect of MAþ compared to MA−; Step 3 effect represents effect of MA group only at mean level of lifetime average daily alcohol use.
d Step 3 effect represents effect of lifetime average daily alcohol use in MA− individuals only (reference group).
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examined the independent effect of MA status while control-
ling for WRAT scores, lifetime MDD, and lifetime average
daily cannabis use, demonstrated significantly lower global
T scores in the MAþ group compared to the MA– group
(b=−1.75, p= .034). Of the covariates examined, only
WRAT scores independently predicted global T scores, with
higher WRAT performance predicting higher global T scores
(b= .09, p= .020). Step 2, which added lifetime average
daily alcohol use and days since last alcohol use as predictors
of global T scores, did not demonstrate a significant effect of
lifetime average daily alcohol use on global functioning inde-
pendent of MA status and covariates (b=−.08, p= .502).
Step 3, which examined whether lifetime average daily alco-
hol use modulated the effects ofMA status on global T scores,
showed a significant interaction of lifetime average daily
alcohol use and MA status for global performance (b= .50,
p= .044). Simple slope analyses indicated that lifetime aver-
age daily alcohol use negatively related to global functioning
among MA− persons (b=−0.44, p= .030), but did not sig-
nificantly predict global functioning among MAþ partici-
pants (b= 0.08, p= .586; Figure 1). Post-hoc adjustment
for BDI-II scores did not attenuate the significant interaction
effect of lifetime average daily alcohol use and MA status on
global T scores.
Results for the binary logistic regression analysis predict-
ing global impairment are also reported in Table 3. Similar to
the step 1 global T score analyses, the MAþ group had a
higher likelihood of global impairment (OR= 2.05, p= .064)
and higher WRAT scores reduced the likelihood of impair-
ment (OR= 0.96, p= .078), yet these effects only
approached significance. The step 2 model did not demon-
strate significant main effects for lifetime average daily alco-
hol use or days since last alcohol use on probability of global
impairment. However, step 3 showed a significant interaction
of lifetime average daily alcohol use andMA status for global
impairment (p= .003). Simple slope analyses indicated that
greater alcohol consumption increased the likelihood of
global impairment (OR = 1.22, 95% CI [1.01; 1.48],
p= .033) in MA− persons, but significantly decreased the
likelihood of global impairment (OR= 0.82, 95% CI [0.68;
0.96], p= .020) in MAþ individuals. Similar to the T score
analysis, post-hoc adjustment for BDI-II scores did not
attenuate the significant interaction effect of lifetime average
daily alcohol use and MA status on global impairment.
DISCUSSION
The present study explored how lifetime patterns of alcohol
consumption, specifically a metric averaging drinks per
drinking day over the lifetime, related to neuropsychological
performance among MA-dependent and MA-nonusing indi-
viduals. Based on the current literature detailing the indepen-
dent, adverse neurobehavioral contributions of chronic MA
and alcohol consumption, it was hypothesized that the
MAþ group would exhibit worse neurocognitive perfor-
mance and that greater alcohol use would exacerbate the del-
eterious neurocognitive effects of MA use. Consistent with
prior studies, we demonstrate that MAþ individuals perform
worse on average across all neurocognitive domains while
exhibiting modestly higher rates of neurocognitive impair-
ment (Cherner et al., 2010; Scott et al., 2007) and consuming
more alcohol and cannabis than their MA– counterparts.
Whereas heavier drinking increased the likelihood of global
neurocognitive impairment in the absence of MA depend-
ence, no additive effects of alcohol were observed among
MAþ participants. Contrary to expectations, lifetime average
daily alcohol use did not predict global T scores and in fact
was associated with reduced risk of global neurocognitive
impairment in the MAþ group. To our knowledge, this is
the first study to explore potentially modulating effects
of historical patterns of alcohol consumption, as opposed
to recent heavy drinking, on MA-associated neurocognitive
performance.
Given the known neurotoxic and neurobehavioral conse-
quences of heavy alcohol use (Brust, 2010; Grant, 1987),
these results must be interpreted with caution. However,
our finding that elevated historical levels of alcohol consump-
tion attenuate MA-related global neurocognitive impairment
Fig. 1. Global T scores by lifetime average daily alcohol use, with predicted slopes for methamphetamine dependence (MA) status groups
controlling for WRAT, BDI-II, lifetime MDD, days since last alcohol use, and lifetime average daily cannabis use. Higher lifetime average
daily alcohol use significantly predicts lower global T scores among MA− individuals only.
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is consistent with prior studies demonstrating that singly
addicted stimulant abusers consistently experience greater
levels of neurocognitive dysfunction than those who simulta-
neously abuse stimulants and alcohol (Lawton-Craddock
et al., 2003; Robinson et al., 1999). These prior findings
are particularly applicable to the current investigation as both
studies classified participants based on lifetime patterns of
chronic stimulant and alcohol use (i.e., dependence) and
administered comprehensive and validated neuropsychologi-
cal batteries. Although studies of the neurocognitive effects
of acute, combined stimulant and alcohol use may be less
generalizable to our results, some studies have reported that
administration of dextroamphetamine or amphetamine sul-
fate following ethanol-induced intoxication in humans may
dampen ethanol-related neuropsychological decrements in
psychomotor performance, executive function, and working
memory (Perez-Reyes et al., 1992; Wilson et al., 1966).
Nevertheless, further research is required to determine
whether acute alcohol administration following MA-induced
intoxication exhibits similar neurocognitive effects and to
what extent such findings can be extrapolated to chronic sub-
stance abusers.
Our unanticipated results with respect to MAþ partici-
pants necessitate that we critically examine potential statisti-
cal and behavioral confounds. The significant relationship
between lifetime average daily alcohol use and the dichoto-
mous global impairment variable, as opposed to the null
effect of lifetime alcohol use on continuous global T scores,
reflects fundamental differences between these two measures
of global neurocognition. Global T scores are computed by
averaging individual T scores across the entire battery and
can represent performance across the entire neurocognitive
spectrum (e.g., severely impaired to very superior). As a
result, above average performance on some measures can
mask impaired performance elsewhere. Conversely, the
GDS-based impairment classification accounts for the fre-
quency and severity of deficits across the test battery with less
consideration given to performance in the normal range (i.e.,
normal scores are set to zero; Blackstone et al., 2012).
Figure 1 demonstrates that although average global T scores
in MAþ individuals remain stable as lifetime average daily
alcohol use increases, resulting in a null association, there
is greater variability in performance at low levels of alcohol
use, resulting in a higher percentage of MAþ individuals
being classified as impaired on the GDS at low levels of
use. Similarly, the MAþ group had an average global T score
that only fell .35 standard deviations below the mean (i.e.,
T= 47.5), yet was twice as likely to have global impairment
as compared to MA– individuals, suggesting that a global
index of impairment may enhance detection of the subset
of MA users that are disproportionally vulnerable to MA-
related brain insults. Conversely, MA group comparisons
on domain-specific performance illustrate the utility of T
scores in detecting subtle yet significant differences that do
not necessarily translate to differences in rates of impairment.
The hypothesis that neurocognitive performance attributable
to MA-induced neural injury may hinder the ability to detect
the relatively subtle influence of alcohol is supported by evi-
dence that MA abuse poses greater risk for neurocognitive
deficits than alcohol abuse (Bechara & Martin, 2004;
Gonzalez et al., 2007). Although our data demonstrate an
adverse, multi-domain effect of MA dependence, this effect
is modest and therefore unlikely to preclude us from detecting
any additional influence of alcohol use patterns.
From a polysubstance use perspective, the strong positive
correlation between self-reported lifetime MA and alcohol
use indicates that the observed relationship between greater
alcohol use and lower likelihood of global neurocognitive
impairment is not an artifact of heavy drinkers having less
exposure to MA. Although cannabis use correlated with alco-
hol use, and prior evidence suggests cannabis use may attenu-
ate MA-related neurocognitive deficits (Gonzalez et al.,
2004), lifetime cannabis exposure did not suppress our sig-
nificant findings nor did it account for variance in neurocog-
nitive performance. Furthermore, the negligible effects of
days since last alcohol use and depressive symptoms rule
out MA group differences in recent alcohol consumption
and psychiatric comorbidities as a source of variance in neu-
rocognitive performance. In a meta-analysis examining the
neurocognitive effects of duration of alcohol abstinence,
Stavro and colleagues found that neurocognitive dysfunction
decreased following sustained abstinence for at least a year
(Stavro et al., 2013). Importantly, this meta-analysis only
included patients who met criteria for alcohol use disorder
and excluded patients with non-alcohol substance use
disorders. Given that the present study sample included MA-
dependent individuals with varying levels of alcohol con-
sumption, neurocognitive recovery facilitated by increased
duration of abstinence from alcohol may be more prominent
for heavier drinking populations without comorbid substance
use disorders. Moreover, our study criteria excluded DSM-
IV-based alcohol dependence within the past year as well
as evidence of long-term lifetime alcoholism. Therefore,
those meeting dependence criteria would have done so only
in the past and on an episodic basis. With regard toMA group
differences in time since last alcohol use, these are largely
explained by many MAþ participants being in recovery
and abstaining from all substances currently, whereas
MA– participants may include current social drinkers.
Nevertheless, days since last alcohol use did not predict
our outcomes.
Drawing inferences about specific biological mechanisms
underlying polysubstance use in humans is particularly chal-
lenging given that substance use disorders, such as MA
dependence, cannot be experimentally modeled as indepen-
dent factors in randomized controlled trials, and observatio-
nal studies are often underpowered to examine potential
confounds. Although the nature of our data prevents us from
empirically investigating specific biological mechanisms that
may explain the interactive effects of MA status and lifetime
average daily alcohol use on neurocognitive functioning, we
offer several plausible neurobiological interpretations. First,
the cerebrovascular abnormalities evidenced in MA use are
partially attributable to the vasoconstrictive properties of
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MA that result in platelet aggregation (Ho et al., 2009;
Kiyatkin & Sharma, 2009). Alcohol, in contrast, is recog-
nized to have vasodilating properties that reduce platelet
aggregation (Bau et al., 2005). Thus, alcohol-driven attenu-
ation of MA-induced vasoconstriction may reduce the mag-
nitude of neurovascular dysfunction and subsequent
neurobehavioral deficits experienced by MA users. It is
important to note, however, that certain studies have demon-
strated a biphasic vasoregulatory effect in which alcohol’s
vasodilating properties may be limited to light-to-moderate
drinkers, whereas heavier drinkers are at risk for a rebound
effect in which an increase in platelet aggregation is observed
following acute withdrawal from alcohol (Piano, 2017;
Renaud & Ruf, 1996).
An additional source of MA-associated neurotoxicity is
the induction of brain hyperthermia through increased neural
activation (Brown et al., 2003; Kiyatkin & Sharma, 2009).
Brain thermotoxicity is mediated through multi-level mech-
anisms in which adverse cellular (e.g., protein denaturation),
local (e.g., infarction), and systemic (e.g., cerebral blood flow
dysregulation) events can contribute to neurocognitive diffi-
culties (Walter & Carraretto, 2016). Despite the sensations of
warmth experienced during alcohol consumption, alcohol’s
vasodilatory properties result in brain and body heat dissipa-
tion (Lee et al., 1990) that may counteract the hyperthermic
consequences of MA use. Animal experiments have demon-
strated that rats exposed to alcohol before and after TBI
recover from TBI-induced brain hyperthermia faster and
exhibit fewer deficits in spatial learning than alcohol-naïve
rats (Janis et al., 1998; Taylor et al., 2002). Whether such
thermoregulatory benefits of alcohol, and subsequent attenu-
ation of neurocognitive impairments, hold in the context of
MA-induced hyperthermia requires further investigation.
Although the neurophysiological alterations associated
with increased alcohol consumption may provide neuropro-
tective benefits in the context of MA addiction, our data dem-
onstrate an adverse effect of lifetime average daily alcohol
use on neurocognitive function in the absence ofMA depend-
ence. Unlike theMAþ group, who on average reported heavy
lifetime alcohol consumption (i.e., >4 drinks/day), MA−
individuals on average reported low-risk alcohol intake
(National Institute on Alcohol Abuse and Alcoholism
(U.S.), 2005). Neurocognitive performance in nondrinkers,
low, and moderate drinkers has been widely studied yet
has yielded mixed results. Whereas many researchers posit
a “j-shaped” relationship, in which light-to-moderate con-
sumption confers neurocognitive benefits over nondrinking
but heavy consumption is more neurotoxic than abstinence
(Britton et al., 2004; Elias et al., 1999; Neafsey & Collins,
2011; Rodgers et al., 2005), other studies have either found
no relationship or a negative association between low-to-
moderate consumption and neurobehavioral outcomes
(Gross et al., 2011; Kalapatapu et al., 2017; Topiwala
et al., 2017). Our findings are most consistent with the latter
group of studies suggesting a deleterious dose-dependent
effect of alcohol consumption, even at moderate levels, on
cognition and brain structure (Gross et al., 2011; Topiwala
et al., 2017). It is important to note that despite reaching stat-
istical significance, our findings represent a small effect size
in which one extra drink per day equates to about a one-half
unit decrease in global T scores. As a result, the clinical sig-
nificance of this relationship may be far more relevant for
heavier drinkers with borderline neurocognitive performance
than higher performing drinkers. Although the present study
focuses on the conditional role of alcohol in MA-related neu-
rocognitive performance, further studies that probe the neuro-
cognitive effect of alcohol at varying levels of consumption
and model non-linear relationships are warranted regardless
of MA status.
Understanding limitations of the current study may guide
future research to clarify the observed differential effects of
alcohol use on neurocognitive functioning among MAþ
and MA− individuals. Unsurprisingly, the MAþ group dis-
played significantly greater lifetime average daily alcohol use
than the MA− group. Although the distribution of residuals
from regression models were carefully examined to ensure no
assumptions of normality were violated, the group difference
in lifetime average daily alcohol use may impact the reliabil-
ity of our MA effect estimates at high levels of consumption
in which the MA– group is underrepresented. Additionally,
these estimates of lifetime alcohol consumption are fully
dependent on participant self-report. Given that the vast
majority of participants began drinking during teenage years
and must therefore recall multiple decades of alcohol use,
estimates of alcohol consumption will naturally deviate from
the true amount of alcohol exposure. Consequently, it is
recommended that our estimates related to alcohol use and
neurocognition be interpreted conservatively with a greater
emphasis on directionality than exact magnitude.
The cross-sectional nature of our data prevents us from
disentangling the effects of alcohol and MA use from long-
standing individual differences in neurocognitive capacities
(e.g., cognitive reserve). However, the inclusion of the
WRAT Reading subtest as a covariate in all regression mod-
els increases our confidence that the observed effects of sub-
stance use on neurocognitive performance are not attributable
to premorbid functioning. Furthermore, the application of
demographic corrections to neuropsychological test scores
improves the comparison of results between the MA groups
despite differences in education. The positive association
between WRAT scores and global neurocognition highlights
the incremental predictive value of the WRAT above and
beyond demographic effects, most notably education.
These findings alignwith prior substance use studies that sug-
gest that intellectual enrichment, as indicated by high IQ, can
increase cognitive reserve and mitigate the deleterious
effects of stimulant-induced neural injury on neurocognition
(Cherner et al., 2010; Mahoney et al., 2017). Unsurprisingly,
MAþ individuals more frequently met criteria for lifetime
dependence for other substance use than MA– individuals.
However, study exclusion criteria necessitated that such
dependence be episodic in nature and remote (>5 years
ago; alcohol >1 year ago; cannabis no restriction).
Additional individual differences that we were not able to
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capture in the present study include potential genetic
differences in vulnerability to alcohol effects (e.g., metabolic
differences); however, these would presumably be equally
distributed among MAþ and MA– individuals.
The unexpected finding that alcohol reduces the likelihood
of neurocognitive impairment in MAþ individuals raises
intriguing biologically driven theories of neuroprotection that
we unfortunately cannot answer with our data. Simultaneous
administration of MA and alcohol versus non-overlapping
periods of single substance use is an issue central to concep-
tualizing the interaction between MA and alcohol use. Many
primary MA users report alternating use of MA and alcohol
throughout a given binge in order to titrate their subjective
experience of intoxication (Park & Nordahl, 2014). This
coordinated pattern of MA and alcohol use may attenuate
MA-related sleep disturbances, but may also increase risky
behaviors (e.g., impaired driving) due to decreased percep-
tions of intoxication (Kirkpatrick et al., 2012). Although
the lifetime average daily alcohol use metric captures lifetime
alcohol patterns, it does not capture chronicity and persist-
ence of alcohol use nor does it distinguish periods of concur-
rentMA and alcohol use from intervals of monosubstance use
among theMAþ individuals. Such a distinction between life-
time periods of simultaneous intoxication versus non-over-
lapping intoxication would permit for a more nuanced
understanding of the aforementioned neurophysiological
hypotheses. Additionally, although our neurocognitive vari-
ables reflect the behavioral outputs of neural functioning,
they do not directly measure the integrity of neural circuitry
and neurobiological activity. Therefore, the inclusion of
genetic, neuroimaging, and fluid-based biomarker data that
more directly reflect neurobiological pathways is recom-
mended for future studies of polysubstance use.
CONCLUSION
Taken together, our findings demonstrate a differential
effect of lifetime alcohol consumption on neurocognitive
performance such that hypothesized deleterious contributions
of alcohol use were only detected in MA-nonusing individ-
uals. Contrary to expectations, lifetime average daily alcohol
use was associated with a reduced likelihood of global
neurocognitive impairment in MA-dependent persons. Our
findings are supported by prior animal and human studies
identifying neurobiological mechanisms by which alcohol
may attenuate the vasoconstriction and brain thermotoxicity
associated with stimulant use (i.e., vasodilation and heat dis-
sipation). Alcohol may diminish aspects of the neural
dysregulation cascade that results in MA-associated neuro-
cognitive dysfunction. Replication and examination of
neurophysiologic mechanisms (e.g., neurovascular and
metabolic effects) underlying alcohol use in the context of
MA dependence, including concurrent use as well as acute
and long-term effects, is warranted to elucidate whether
alcohol confers a degree of neuroprotection in MA
dependence.
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